0001437749-20-012741.txt : 20200609 0001437749-20-012741.hdr.sgml : 20200609 20200609163854 ACCESSION NUMBER: 0001437749-20-012741 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200608 FILED AS OF DATE: 20200609 DATE AS OF CHANGE: 20200609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tucker Sean CENTRAL INDEX KEY: 0001652204 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 20952372 MAIL ADDRESS: STREET 1: 385 OYSTER POINT BLVD., SUITE 9A CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 385 OYSTER POINT BOULEVARD, SUITE 9A CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 385 OYSTER POINT BOULEVARD, SUITE 9A CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 4 1 rdgdoc.xml FORM 4 TUCKER X0306 4 2020-06-08 0000072444 Vaxart, Inc. VXRT 0001652204 Tucker Sean C/O VAXART, INC. 385 OYSTER POINT BOULEVARD, SUITE 9A SOUTH SAN FRANCISCO CA 94080 1 Chief Scientific Officer Stock Option (right to buy) 1.70 2020-06-08 4 A 0 360000 0 A 2030-03-23 Common Stock 360000 360000 D The option grant was approved by the board of directors of Vaxart, Inc. on March 24, 2020, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 8, 2020. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on the date of grant, and thereafter in 24 equal monthly installments commencing on the first day of the calendar month following the grant date such that the stock option shall be fully vested on April 1, 2022. /s/ Sean Tucker 2020-06-09